If you're a horror fan who loves the werewolf sub-genre, you’ve been eating well the last couple of months. Universal’s Wolf ...

The latest update is out from Werewolf Therapeutics ( (HOWL)). On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER ...

Matthew Galea is a features writer for CBR. He spends his day as a high school English teacher, and every other minute watching, thinking and writing about movies and television. From Lon Chaney Jr.'s ...

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Of all the creatures found in Halloween lore, none are more mysterious than the fabled werewolf. Only emerging on a full moon night, their howl can send shivers down your spine and get you racing to ...